Drugs

, Volume 67, Issue 18, pp 2727–2746 | Cite as

Management of Epilepsy during Pregnancy

Review Article

Abstract

Managing epilepsy during pregnancy is to balance the maternal and fetal risks associated with uncontrolled seizures against the potential teratogenic effects of antiepileptic drugs (AEDs). A rational approach requires knowledge of such risks as well as an understanding of the effects of pregnancy on seizure control and of gestational effects on AED disposition. Uncontrolled tonic-clonic seizures are potentially hazardous to the mother and, although strict evidence is lacking, are generally also assumed to be more harmful to the fetus than are AEDs. However, infants who have been exposed to AEDs in utero run an increased risk of congenital malformations: approximately twice the rate reported in the general population. Earlier literature has largely failed to demonstrate differences in birth defect rates with different treatment regimens, which can be ascribed mainly to insufficient sample sizes. More recent data have indicated higher malformation rates with exposure to valproic acid compared with some other major AEDs. The teratogenic effects of valproic acid appear to be dose dependent, with higher risks at dosage levels >1000 mg/day. Polytherapy involving treatment with more than one AED also seems to be associated with an increased risk of birth defects compared with monotherapy. Recently, a few small-scale studies have investigated the possibility that exposure to AEDs in utero may adversely affect the postnatal cognitive development of the offspring. Some of these studies have suggested that valproic acid poses a higher risk compared with other AEDs in this respect. These signals are important, but must be interpreted with caution because of the methodological shortcomings of the studies and because adequately powered prospective studies are necessary to draw firm conclusions. More reassuring findings have emerged regarding the obstetric outcome of pregnancy and the risk of worsening of epilepsy during pregnancy. In particular, it seems that the risk of obstetric complications is not significantly increased. Furthermore, most of the women with epilepsy have no change in their seizure frequency during pregnancy. The disposition of many AEDs may change during pregnancy, reflected in declining plasma drug concentrations. This seems to be most pronounced for lamotrigine and possibly also for oxcarbazepine, and can result in break-through seizures.

The common treatment strategy has been to use the appropriate AED for the woman’s seizure disorder as monotherapy in the lowest effective dosage throughout pregnancy, the objective being to use AEDs in such a way that generalised tonic-clonic seizures are avoided but with minimised risks to the fetus, the newborn and the breast-fed infant. Valproic acid should be avoided if possible. Any major change in the treatment of a woman with epilepsy should ideally be completed before conception. Regular monitoring of drug concentrations is recommended during pregnancy, in particular for lamotrigine and oxcarbazepine.

References

  1. 1.
    Gaily E. Development and growth in children of epileptic mothers: a prospective controlled study. Acta Obstet Gynecol Scand 1991; 70(7-8): 631–2CrossRefGoogle Scholar
  2. 2.
    Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344(15): 1132–8PubMedCrossRefGoogle Scholar
  3. 3.
    Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004 Jun; 6(2): 57–75PubMedGoogle Scholar
  4. 4.
    Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000 Sep; 41(2): 107–39PubMedCrossRefGoogle Scholar
  5. 5.
    Adab N, Tudur SC, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy (Cochrane Review). The Cochrane Library. Chichester (UK); John Wiley and Sons, 2004Google Scholar
  6. 6.
    Lipka K, Bulow HH. Lactic acidosis following convulsions. Acta Anaesthesiol Scand 2003 May; 47(5): 616–8PubMedCrossRefGoogle Scholar
  7. 7.
    Hiilesmaa VK, Bardy A, Teramo K. Obstetric outcome in women with epilepsy. Am J Obstet Gynecol 1985; 152(5): 499–504PubMedGoogle Scholar
  8. 8.
    Teramo K, Hiilesmaa V, Bardy A, et al. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7(1): 3–6PubMedCrossRefGoogle Scholar
  9. 9.
    Teramo K, Hiilesmaa V. Pregnancy and fetal complications in epileptic pregnancies. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 53–9Google Scholar
  10. 10.
    The EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006 Feb 14; 66(3): 354–60CrossRefGoogle Scholar
  11. 11.
    Katz O, Levy A, Wiznitzer A, et al. Pregnancy and perinatal outcome in epileptic women: a population-based study. J Matern Fetal Neonatal Med 2006 Jan; 19(1): 21–5PubMedCrossRefGoogle Scholar
  12. 12.
    Richmond JR, Krishnamoorthy P, Andermann E, et al. Epilepsy and pregnancy: an obstetric perspective. Am J Obstet Gynecol 2004; 190(2): 371–9PubMedCrossRefGoogle Scholar
  13. 13.
    Schmidt D. The effect of pregnancy on the natural history of epilepsy. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 3–14Google Scholar
  14. 14.
    Bardy AH. Incidence of seizures during pregnancy, labor and puerperium in epileptic women: a prospective study. Acta Neurol Scand 1987; 75(5): 356–60PubMedCrossRefGoogle Scholar
  15. 15.
    Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 1985; 39(1): 33–41PubMedGoogle Scholar
  16. 16.
    Tomson T, Lindbom U, Ekqvist B, et al. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994 Jan–Feb; 35(1): 122–30PubMedCrossRefGoogle Scholar
  17. 17.
    Remillard G, Dansky L, Andermann E, et al. Seizure frequency during pregnancy and puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 15–25Google Scholar
  18. 18.
    Canger R, Avanzini G, Battino D, et al. Modifications of seizure frequency in pregnant patients with epilepsy: a prospective study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 33–8Google Scholar
  19. 19.
    Schmidt D, Canger R, Avanzini G, et al. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983; 46(8): 751–5PubMedCrossRefGoogle Scholar
  20. 20.
    Nogales Gaete J. The frequency of crises in epileptic women during pregnancy: a prospective study. Rev Med Chil 1986; 114(11): 1052–7PubMedGoogle Scholar
  21. 21.
    Bag S, Behari M, Ahuja GK, et al. Pregnancy and epilepsy. J Neurol 1989; 236(5): 311–3PubMedCrossRefGoogle Scholar
  22. 22.
    Kaneko S. A rational antiepileptic drug therapy of epileptic women in child bearing age. Jpn J Psychiatry Neurol 1988; 42(3): 473–82PubMedGoogle Scholar
  23. 23.
    Battino D, Binelli S, Bossi L, et al. Monitoring of antiepileptic drugs and hormones in pregnant epileptic women. In: Porter RJ, Mattson RH, Ward AA, et al., editors. Advances in epileptology: the XVth Epilepsy International Symposium. New York: Raven Press, 1984: 227–32Google Scholar
  24. 24.
    Specchio LM, La Neve A, Ostillio G, et al. Frequenza delie crisi epilettiche durante la gravidanza in un’osservazione prospettica. Boll Lega It Epil 1989; 66/67: 299–301Google Scholar
  25. 25.
    Wilhelm J, Morris D, Hotham N. Epilepsy and pregnancy: a review of 98 pregnancies. Aust N Z J Obstet Gynaecol 1990; 30(4): 290–5PubMedCrossRefGoogle Scholar
  26. 26.
    Lander CM, Eadie MJ. Plasma antiepileptic drug concentrations during pregnancy. Epilepsia 1991; 32(2): 257–66PubMedCrossRefGoogle Scholar
  27. 27.
    Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42 (4 Suppl. 5): 75–82PubMedGoogle Scholar
  28. 28.
    Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology 1992; 42 (4 Suppl. 5): 89–93PubMedGoogle Scholar
  29. 29.
    Kilpatrick CJ, Hopper JL. The effect of pregnancy on the epilepsies: a study of 37 pregnancies. AustN Z J Med 1993; 23(4): 370–3CrossRefGoogle Scholar
  30. 30.
    Vidovic MI, Delia Marina BM. Trimestral changes of seizure frequency in pregnant epileptic women. Acta Med Croatica 1994; 48(2): 85–7PubMedGoogle Scholar
  31. 31.
    Sabers A, Rogvi-Hansen B, Dam M, et al. Pregnancy and epilepsy: a retrospective study of 151 pregnancies. Acta Neurol Scand 1998; 97(3): 164–70PubMedCrossRefGoogle Scholar
  32. 32.
    Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33(2–3): 145–58PubMedCrossRefGoogle Scholar
  33. 33.
    Thomas SV, Devi GC, Radhakrishnan K, et al. Seizure pattern during pregnancy and puerperium among women with epilepsy [abstract]. Epilepsia 2001; 41 Suppl. 7: 98Google Scholar
  34. 34.
    Gjerde IO, Strandjord RE, Bakke OM, et al. Epilepsy and pregnancy: seizure incidence and serum concentration of antiepileptic agents. Tidsskr Nor Laegeforen 1985; 105(31): 2207–9PubMedGoogle Scholar
  35. 35.
    Lander CM, Edwards VE, Eadie MJ, et al. Plasma anticonvulsant concentrations during pregnancy. Neurology 1977; 27(2): 128–31PubMedCrossRefGoogle Scholar
  36. 36.
    Krishnamurthy K, Sundstrom D, Beaudoin J, et al. Pregnant women with epilepsy taking older anticonvulsants must have their drug levels checked frequently to avoid seizures [abstract]. Epilepsia 2002; 43 Suppl. 7: 232–3Google Scholar
  37. 37.
    Gjerde IO, Strandjord RE, Ulstein M. The course of epilepsy during pregnancy: a study of 78 cases. Acta Neurol Scand 1988; 78(3): 198–205PubMedCrossRefGoogle Scholar
  38. 38.
    Remilliard G, Dansky L, Andermann E, et al. Seizure frequency during pregnancy and the puerperium. In: Janz D, Dam M, Bossi L, et al. editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 15–26Google Scholar
  39. 39.
    Schmidt D. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 39–49Google Scholar
  40. 40.
    Nau H, Kuhnz W, Egger HJ, et al. Anticonvulsants during pregnancy and lactation: transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982; 7(6): 508–43PubMedCrossRefGoogle Scholar
  41. 41.
    Kuhnz W, Koch S, Jakob S, et al. Ethosuximide in epileptic women during pregnancy and lactation period: placental transfer, serum concentrations in nursed infants and clinical status. Br J Clin Pharmacol 1984; 18(5): 671–7PubMedCrossRefGoogle Scholar
  42. 42.
    Pienimaki P, Hartikainen AL, Arvela P, et al. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 1995; 36(3): 241–8PubMedCrossRefGoogle Scholar
  43. 43.
    Bulau P, Paar WD, von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 1988; 34(3): 311–3PubMedCrossRefGoogle Scholar
  44. 44.
    Challier JC, Rey E, Bintein T, et al. Passage of S(+) and R(−) gamma-vinyl-GABA across the human isolated perfused placenta. Br J Clin Pharmacol 1992; 34(2): 139–43PubMedCrossRefGoogle Scholar
  45. 45.
    Pienimaki P, Lampela E, Hakkola J, et al. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997; 38(3): 309–16PubMedCrossRefGoogle Scholar
  46. 46.
    Kimura S. Zonisamide: its placental transport, biological half-life in the newborn, and transport to mother’s milk. A study of a case of an infant born of a mother who had been treated with zonisamide alone during pregnancy. No To Hattatsu 1998 Jul; 30(4): 350–1Google Scholar
  47. 47.
    Tran A, O’Mahoney T, Rey E, et al. Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. Br J Clin Pharmacol 1998; 45(4): 409–11PubMedCrossRefGoogle Scholar
  48. 48.
    Myllynen P, Pienimaki P, Jouppila P, et al. Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia 2001; 42(11): 1482–5PubMedCrossRefGoogle Scholar
  49. 49.
    Kawada K, Itoh S, Kusaka T, et al. Pharmacokinetics of zonisamide in perinatal period. Brain Dev 2002 Mar; 24(2): 95–7PubMedCrossRefGoogle Scholar
  50. 50.
    Öhman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia 2002 Oct; 43(10): 1157–60PubMedCrossRefGoogle Scholar
  51. 51.
    Myllynen PK, Pienimaki PK, Vahakangas KH. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur J Clin Pharmacol 2003 Feb; 58(10): 677–82PubMedGoogle Scholar
  52. 52.
    Öhman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005 Oct; 46(10): 1621–4PubMedCrossRefGoogle Scholar
  53. 53.
    Mirkin BL. Placental transfer and neonatal elimination of diphenylhydantoin. Am J Obstet Gynecol 1971; 109(6): 930–3PubMedGoogle Scholar
  54. 54.
    Ploman L, Persson BH. On the transfer of barbiturates to the human foetus and their accumulation in some of its vital organs. J Obstet Gynaecol Br Emp 1957; 64(5): 706–11PubMedCrossRefGoogle Scholar
  55. 55.
    Nau H, Rating D, Hauser I, et al. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. Eur J Clin Pharmacol 1980 Jul; 18(1): 31–42PubMedCrossRefGoogle Scholar
  56. 56.
    Pynnönen S, Kanto J, Sillanpää M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol 1977; 41(3): 244–53CrossRefGoogle Scholar
  57. 57.
    Perucca E. Drug metabolism in pregnancy, infancy and childhood. Pharmacol Ther 1987; 34(1): 129–43PubMedCrossRefGoogle Scholar
  58. 58.
    Krauer B, Krauer F. Drug kinetics in pregnancy. Clin Pharmacokinet 1977; 2(3): 167–81PubMedCrossRefGoogle Scholar
  59. 59.
    Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and puerperium. Clin Pharmacokinet 2007; 46(3): 209–19PubMedCrossRefGoogle Scholar
  60. 60.
    Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992 Apr; 42 (4 Suppl. 5): 12–6PubMedGoogle Scholar
  61. 61.
    Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990 Apr; 5(3): 223–8PubMedCrossRefGoogle Scholar
  62. 62.
    Battino D, Avanzini G, Bossi L, et al. Monitoring of antiepileptic drugs plasma levels during pregnancy and puerperium. In: Janz D, Dam M, Bossi L, et al.,editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 147–54Google Scholar
  63. 63.
    Bardy AH, Hiilesmaa VK, Teramo KA. Serum phenytoin during pregnancy, labor and puerperium. Acta Neurol Scand 1987; 75(6): 374–5PubMedCrossRefGoogle Scholar
  64. 64.
    Tomson T, Lindbom U, Ekqvist B, et al. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994 Jan–Feb; 35(1): 131–5PubMedCrossRefGoogle Scholar
  65. 65.
    Dansky L, Andermann E, Shervin A, et al. Plasma levels of phenytoin during pregnancy ant the puerperium. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 155–62Google Scholar
  66. 66.
    Battino D, Binelli S, Bossi L, et al. Plasma concentrations of carbamazepine and carbamazepine 10,11-epoxide during pregnancy and after delivery. Clin Pharmacokinet 1985 May-Jun; 10(3): 279–84PubMedCrossRefGoogle Scholar
  67. 67.
    Yerby MS, Friel PN, Miller DQ. Carbamazepine protein binding and disposition in pregnancy. Ther Drug Monit 1985; 7(3): 269–73PubMedCrossRefGoogle Scholar
  68. 68.
    Lander CM, Livingstone I, Tyrer JH, et al. The clearance of anticonvulsant drugs in pregnancy. Clin Exp Neurol 1981; 17: 71–8PubMedGoogle Scholar
  69. 69.
    Battino D, Binelli S, Bossi L, et al. Changes in primidone/ phenobarbitone ratio during pregnancy and the puerperium. Clin Pharmacokinet 1984 May-Jun; 9(3): 252–60PubMedCrossRefGoogle Scholar
  70. 70.
    Rating D, Nau H, Jager-Roman E, et al. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women. Acta Paediatr Scand 1982 Mar; 71(2): 301–11PubMedCrossRefGoogle Scholar
  71. 71.
    Philbert A, Pedersen B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol Scand 1985 Nov; 72(5): 460–3PubMedCrossRefGoogle Scholar
  72. 72.
    Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000 Jun; 41(6): 709–13PubMedCrossRefGoogle Scholar
  73. 73.
    Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002 Jul 23; 59(2): 251–5PubMedCrossRefGoogle Scholar
  74. 74.
    Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004 Jan; 62(2): 292–5PubMedCrossRefGoogle Scholar
  75. 75.
    de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004 Aug; 63(3): 571–3PubMedCrossRefGoogle Scholar
  76. 76.
    Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005 Jul; 65(3): 185–8PubMedCrossRefGoogle Scholar
  77. 77.
    Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006 Oct 10; 67(7): 1297–9PubMedCrossRefGoogle Scholar
  78. 78.
    Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006 Mar; 47(3): 504–9PubMedCrossRefGoogle Scholar
  79. 79.
    Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006 Oct 24; 67(8): 1497–9PubMedCrossRefGoogle Scholar
  80. 80.
    Gramstrom ML. Development of the children of epileptic mothers: preliminary results from the prospective Helsinki study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 403–8Google Scholar
  81. 81.
    Pennell PB, Koganti A, Helmers S, et al. The impact of pregnancy and childbirth on the elimination of levetiracetam [abstract]. Epilepsia 2005 Oct; 46 Suppl. 8: 89Google Scholar
  82. 82.
    Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007 Mar 22; 48(6): 1111–6PubMedCrossRefGoogle Scholar
  83. 83.
    Vajda FJ, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006 Jun; 13(6): 645–54PubMedCrossRefGoogle Scholar
  84. 84.
    Sabers A, Dam MA, Rogvi-Hansen B, et al. Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109(1): 9–13Google Scholar
  85. 85.
    Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004 Oct; 45(10): 1171–5PubMedCrossRefGoogle Scholar
  86. 86.
    Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects (prospective study). Lancet 1976; I(7954): 272–5CrossRefGoogle Scholar
  87. 87.
    Majewski F, Steger M, Richter B, et al. The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Int J Biol Res Pregnancy 1981; 2(1): 37–45PubMedGoogle Scholar
  88. 88.
    Friis ML, Hauge M. Congenital heart defects in live-born children of epileptic parents. Arch Neurol 1985; 42(4): 374–6PubMedCrossRefGoogle Scholar
  89. 89.
    Meyer JG. The teratological effects of anticonvulsants and the effects on pregnancy and birth. Eur Neurol 1973; 10(3): 179–90PubMedCrossRefGoogle Scholar
  90. 90.
    Beck-Mannagetta G, Drees G, Janz D. Malformations and minor anomalies in the offspring of epileptic parents: a retrospective study. In: Janz D, Dam M, Bossi L, et al. editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 317–23Google Scholar
  91. 91.
    Koch S, Hartmann A, Jager E. Major malformation in children of epileptic mothers: due to epilepsy or its therapy? In: Janz D, Dam M, Richens A, et al., editors. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 313–6Google Scholar
  92. 92.
    Rating D, Jager-Roman E, Koch S, et al. Major malformations and minor anomalies in the offspring of epileptic parents: the role of antiepileptic drugs. Pharmacokinetics in teratogenesis. Boca Raton (FL): CRC Press, 1987: 205–24Google Scholar
  93. 93.
    Koch S, Losche G, Jager-Roman E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992; 42 (4 Suppl. 5): 83–8PubMedGoogle Scholar
  94. 94.
    Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 2004; 27(3): 197–202PubMedCrossRefGoogle Scholar
  95. 95.
    Akhtar N, Millac P. Epilepsy and pregnancy: a study of 188 pregnancies in 92 patients. Br J Clin Pract 1987; 41(8): 862–4PubMedGoogle Scholar
  96. 96.
    Al Bunyan M, Abo-Talib Z. Outcome of pregnancies in epileptic women: a study in Saudi Arabia. Seizure 1999; 8(1): 26–9PubMedCrossRefGoogle Scholar
  97. 97.
    Anderman E, Duncan S, Mercho S, et al. Safety of carbamazepine exposure during pregnancy [abstract]. Epilepsia 2003; 44 Suppl. 8: 35Google Scholar
  98. 98.
    Barry JE, Danks DM. Anticonvulsants and congenital abnormalities [letter]. Lancet 1974; II(7871): 48–9CrossRefGoogle Scholar
  99. 99.
    Bertollini R, Kallen B, Mastroiacovo P, et al. Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 1987; 3(2): 164–71PubMedCrossRefGoogle Scholar
  100. 100.
    Buchanan N. Epilepsy and pregnancy: a review of 26 patients. N Z Med J 1988; 101(851): 509–10PubMedGoogle Scholar
  101. 101.
    Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999; 40(9): 1231–6PubMedCrossRefGoogle Scholar
  102. 102.
    Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005 Mar 22; 64(6): 955–60PubMedCrossRefGoogle Scholar
  103. 103.
    Dansky L, Anderman E, Anderman F. Major congenital malformation in the offspring of epileptic patients: genetic and environmental risk factors. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 223–34Google Scholar
  104. 104.
    Duncan S, Mercho S, Lopes-Cendas I, et al. The effects of valproic acid on the outcome of pregnancy: a prospective study [abstract]. Epilepsia 2003; 44 Suppl. 8: 59Google Scholar
  105. 105.
    Elshove J, van Eck JH. Congenital abnormalities, cleft lip and cleft palate in particular, in children of epileptic mothers. Ned Tijdschr Geneeskd 1971 Aug 14; 115(33): 1371–5PubMedGoogle Scholar
  106. 106.
    Eskazan E, Asian S. Antiepileptic therapy and teratogenicity in Turkey. Int J Clin Pharmacol Ther Toxicol 1992; 30(8): 261–4PubMedGoogle Scholar
  107. 107.
    Fabris C, Licata D, Stasiowska B, et al. Newborn infants from epileptic mothers: malformation and auxonologic risk. Pediatr Med Chir 1989; 11(1): 27–31PubMedGoogle Scholar
  108. 108.
    Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000; 321(7262): 674–5PubMedCrossRefGoogle Scholar
  109. 109.
    Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. BMJ 1973; 2(5864): 442–8PubMedCrossRefGoogle Scholar
  110. 110.
    Goujard J, Huel G, Rumeau-Rouquette C. Anti-epileptics and congenital malformations. J Gynecol Obstet Biol Reprod (Paris) 1974; 3(6): 831–42Google Scholar
  111. 111.
    Higgins TA, Comerford JB. Epilepsy in pregnancy. J Ir Med Assoc 1974; 67(11): 317–20PubMedGoogle Scholar
  112. 112.
    Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61(5): 673–8PubMedCrossRefGoogle Scholar
  113. 113.
    Holmes LB, Wyszynski DF, Baldwin EJ, et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract]. Birth Defects Research (Part A): Clinical and Molecular Teratology 2006; 78: 318Google Scholar
  114. 114.
    Hunt SJ, Morrow JI. Safety of antiepileptic drugs during pregnancy. Expert Opin Drug Saf 2005 Sep; 4(5): 869–77PubMedCrossRefGoogle Scholar
  115. 115.
    Hvas CL, Henriksen TB, Ostergaard JR. Birth weight in offspring of women with epilepsy. Epidemiol Rev 2000; 22(2): 275–82PubMedCrossRefGoogle Scholar
  116. 116.
    Janz D, Fuchs U. Are anti-epileptic drugs harmful during pregnancy? Dtsch Med Wochenschr 1964 Feb 7; 89: 241–8PubMedCrossRefGoogle Scholar
  117. 117.
    Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997; 17(3): 561–4PubMedGoogle Scholar
  118. 118.
    Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003 Feb 25; 60(4): 575–9PubMedCrossRefGoogle Scholar
  119. 119.
    Kallen B. Maternal epilepsy, antiepileptic drugs and birth defects. Pathologica 1986; 78(1058): 757–68PubMedGoogle Scholar
  120. 120.
    Katz JM, Pacia SV, Devinsky O. Current management of epilepsy and pregnancy: fetal outcome, congenital malformations, and developmental delay. Epilepsy Behav 2001 Apr; 2(2): 119–23PubMedCrossRefGoogle Scholar
  121. 121.
    Knight AH, Rhind EG. Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients. Epilepsia 1975; 16(1): 99–110PubMedCrossRefGoogle Scholar
  122. 122.
    Kondo T, Kaneko S, Amano Y, et al. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996; 37(12): 1242–4PubMedCrossRefGoogle Scholar
  123. 123.
    Kuenssberg EV, Knox JD. Teratogenic effect of anticonvulsants. Lancet 1973; I(7796): 198CrossRefGoogle Scholar
  124. 124.
    Lander CM, Eadie MJ. Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990; 7(1): 77–82PubMedCrossRefGoogle Scholar
  125. 125.
    Laskowska M, Leszczynska-Gorzelak B, Oleszczuk J. Pregnancy in women with epilepsy. Gynecol Obstet Invest 2001; 51(2): 99–102PubMedCrossRefGoogle Scholar
  126. 126.
    Lekwuwa GU, Adewole IF, Thompson MO. Antiepileptic drugs and teratogenicity in Nigerians. Trans R Soc Trop Med Hyg 1995; 89(2): 227PubMedCrossRefGoogle Scholar
  127. 127.
    Lindhout D, Meinardi H, Barth P. Hazards of fetal exposure to drugs combination. In: Janz D, Dam M, Bossi L, et al. editors. Epilepsy, pregnancy, and the child. New York: Raven Press 1982: 275–82.Google Scholar
  128. 128.
    Lindhout D, Meinardi H, Meijer JW, et al. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42 (4 Suppl. 5): 94–110PubMedGoogle Scholar
  129. 129.
    Loiseau P, Henry TP. Teratogenic hazards in antiepileptic therapy [letter]. Nouv Presse Med 1974; 3(2): 92PubMedGoogle Scholar
  130. 130.
    Lowe CR. Congenital malformations among infants born to epileptic women. Lancet 1973; I(7793): 9–10CrossRefGoogle Scholar
  131. 131.
    Maroni E, Markoff R. Epilepsy and pregnancy. Gynaecologia 1969; 168(6): 418–21PubMedGoogle Scholar
  132. 132.
    Martin F. Pregnancy and epilepsy. Rev Med Suisse Romande 1978; 98(4): 199–208PubMedGoogle Scholar
  133. 133.
    Martin PJ, Millac PA. Pregnancy, epilepsy, management and outcome: a 10-year perspective. Seizure 1993; 2(4): 277–80PubMedCrossRefGoogle Scholar
  134. 134.
    Meischenguiser R, D’Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004; 5(2): 163–7PubMedCrossRefGoogle Scholar
  135. 135.
    Melchior JC, Svensmark O, Trolle D. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 1967 Oct 21; II(7521): 860–1CrossRefGoogle Scholar
  136. 136.
    Montouris G, Creasy G, Khan A, et al. Pregnancy outcome in topiramate-treated pregnancy [abstract]. Epilepsia 2003; 44 Suppl. 9: 290Google Scholar
  137. 137.
    Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003; 4(3): 310–7PubMedCrossRefGoogle Scholar
  138. 138.
    Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006 Feb; 77(2): 193–8PubMedCrossRefGoogle Scholar
  139. 139.
    Niswander JD, Wertelecki W. Congenital malformation among offspring of epileptic women [letter]. Lancet 1973; I(7811): 1062CrossRefGoogle Scholar
  140. 140.
    Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68(1): 18–24PubMedCrossRefGoogle Scholar
  141. 141.
    Oguni M, Dansky L, Andermann E, et al. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992; 14(6): 371–80PubMedCrossRefGoogle Scholar
  142. 142.
    Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998; 39(8): 887–92PubMedCrossRefGoogle Scholar
  143. 143.
    Omtzigt JG, Los FJ, Hagenaars AM, et al. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn 1992; 12(11): 893–7PubMedCrossRefGoogle Scholar
  144. 144.
    Pandian JD, Abraham M, Chacko B, et al. Pregnancy and epilepsy: results of Ludhiana Center of Indian Registry for Epilepsy and Pregnancy [abstract]. 25th International Epilepsy Congress; 2003 Oct 12–16; LisbonGoogle Scholar
  145. 145.
    Sabin M. Epilepsy and pregnancy. Obstet Gynecol 1956; 7(2): 175–9PubMedGoogle Scholar
  146. 146.
    Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997 Sep; 38(9): 981–90PubMedCrossRefGoogle Scholar
  147. 147.
    Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46(5): 739–46PubMedCrossRefGoogle Scholar
  148. 148.
    Sawhney H, Vasishta K, Suri V, et al. Pregnancy with epilepsy: a retrospective analysis. Int J Gynaecol Obstet 1996; 54(1): 17–22PubMedCrossRefGoogle Scholar
  149. 149.
    Sonneveld SW, Correy JF. Outcome of pregnancies complicated by epilepsy in Tasmania 1981–1988. Aust N Z J Obstet Gynaecol 1990; 30(4): 286–9PubMedCrossRefGoogle Scholar
  150. 150.
    South J. Teratogenic effect of anticonvulsants. Lancet 1972; II(7787): 1154CrossRefGoogle Scholar
  151. 151.
    Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of fetus and the newborn. Lancet 1972; II(7782): 839–43CrossRefGoogle Scholar
  152. 152.
    Starreveld-Zimmerman AA, van der Kolk WJ, Meinardi H, et al. Are anticonvulsants teratogenic? Lancet 1973; II(819): 48–9CrossRefGoogle Scholar
  153. 153.
    Svigos JM. Epilepsy and pregnancy. Aust N Z J Obstet Gynaecol 1984; 24(3): 182–5PubMedCrossRefGoogle Scholar
  154. 154.
    Viinikainen K, Heinonen S, Eriksson K, et al. Communitybased, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006; 47(1): 186–92PubMedCrossRefGoogle Scholar
  155. 155.
    Watson JD, Spellacy WN. Neonatal effects of maternal treatment with the anticonvulsant drug diphenylhydantoin. Obstet Gynecol 1971; 37(6): 881–5PubMedGoogle Scholar
  156. 156.
    Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64(6): 961–5PubMedCrossRefGoogle Scholar
  157. 157.
    Yerby MS, Leavitt A, Erickson DM, et al. Antiepileptics and the development of congenital anomalies. Neurology 1992; 42 (4 Suppl. 5): 132–40PubMedGoogle Scholar
  158. 158.
    Annegers JF, Hauser I. The frequency of malformations in relative of patients with epilepsy. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 267–3Google Scholar
  159. 159.
    Deblay MF, Vert P, Andre M. Children of epileptic mothers [in French]. Nouv Presse Med 1982; 11(3): 173–6PubMedGoogle Scholar
  160. 160.
    Gaily E, Granstrom ML, Hiilesmaa V, et al. Minor anomalies in offspring of epileptic mothers. J Pediatr 1988; 112(4): 520–9PubMedCrossRefGoogle Scholar
  161. 161.
    Holmes LB, Rosenberger PB, Harvey EA, et al. Intelligence and physical features of children of women with epilepsy. Teratology 2000; 61(3): 196–202PubMedCrossRefGoogle Scholar
  162. 162.
    Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320(25): 1661–6PubMedCrossRefGoogle Scholar
  163. 163.
    Kelly TE, Edwards P, Rein M, et al. Teratogenicity of anticonvulsant drugs: II, a prospective study. Am J Med Genet 1984; 19(3): 435–43PubMedCrossRefGoogle Scholar
  164. 164.
    Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002 Dec; 11(8): 512–8PubMedCrossRefGoogle Scholar
  165. 165.
    Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006 Aug 8; 67(3): 407–12PubMedCrossRefGoogle Scholar
  166. 166.
    Steegers-Theunissen RP, Renier WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multi-centre prospective study. Epilepsy Res 1994; 18(3): 261–9PubMedCrossRefGoogle Scholar
  167. 167.
    Thomas D, Buchanan N. Teratogenic effects of anticonvulsants [letter]. J Pediatr 1981; 99(1): 163PubMedCrossRefGoogle Scholar
  168. 168.
    Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005 Jun 14; 64(11): 1874–8PubMedCrossRefGoogle Scholar
  169. 169.
    Biale Y, Lewenthal H, Aderet NB. Congenital malformations due to anticonvulsive drugs. Obstet Gynecol 1975; 45(4): 439–42PubMedGoogle Scholar
  170. 170.
    Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984; 18(4): 211–6PubMedCrossRefGoogle Scholar
  171. 171.
    Bjerkedal T. Outcome of pregnancy in women with epilepsy, Norway, 1967 to 1978: congenital malformations. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 289–96Google Scholar
  172. 172.
    Burja S, Rakovec-Felser Z, Treiber M, et al. The frequency of neonatal morbidity after exposure to antiepileptic drugs in utero: a retrospective population-based study. Wien Klin Wochenschr 2006; 118 Suppl. 2: 12–6CrossRefGoogle Scholar
  173. 173.
    Giraud JR, Hoppeler JM, Mettey R, et al. The teratogenic risks of anti-epileptic treatment. J Gynecol Obstet Biol Reprod 1982; 11(3): 385–91Google Scholar
  174. 174.
    Kaneko S, Otani K, Kondo T, et al. Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992; 42 (4 Suppl. 5): 68–74PubMedGoogle Scholar
  175. 175.
    Laine-Cessac P, Le Jaoen S, Rosenau L, et al. Uncontrolled retrospective study of 75 pregnancies in women treated for epilepsy. J Gynecol Obstet Biol Reprod (Paris) 1995; 24(5): 537–42Google Scholar
  176. 176.
    Markestad T, Ulstein M, Strandjord RE, et al. Anticonvulsant drug therapy in human pregnancy: effects on serum concentrations of vitamin D metabolites in maternal and cord blood. Am J Obstet Gynecol 1984; 150(3): 254–8PubMedGoogle Scholar
  177. 177.
    Millar JH, Nevin NC. Congenital malformations and anticonvulsant drugs [letter]. Lancet 1973; I(7798): 328CrossRefGoogle Scholar
  178. 178.
    Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991; 8(1): 75–8PubMedCrossRefGoogle Scholar
  179. 179.
    Seino M, Miyakoshi M. Teratogenic risks of antiepileptic drugs in respect to the type of epilepsy. Folia Psychiatr Neurol Jpn 1979; 33(3): 379–85PubMedGoogle Scholar
  180. 180.
    Stanley FJ, Priscott PK, Johnston R, et al. Congenital malformations in infants of mothers with diabetes and epilepsy in Western Australia, 1980–1982. Med J Aust 1985; 143(10): 440–2PubMedGoogle Scholar
  181. 181.
    Waters CH, Belai Y, Gott PS, et al. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994; 51(3): 250–3PubMedCrossRefGoogle Scholar
  182. 182.
    Weber M, Schweitzer M, Andre JM, et al. Epilepsy, anticonvulsants and pregnancy. Arch Fr Pediatr 1977; 34(4): 374–83PubMedGoogle Scholar
  183. 183.
    Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93(2): 174–6PubMedCrossRefGoogle Scholar
  184. 184.
    Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39(4): 251–9PubMedCrossRefGoogle Scholar
  185. 185.
    Diav-Citrin O, Shechtman S, Arnon J, et al. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology 2001; 57(2): 321–4PubMedCrossRefGoogle Scholar
  186. 186.
    D’Souza SW, Robertson IG, Donnai D, et al. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. Arch Dis Child 1991; 66(3): 320–4PubMedCrossRefGoogle Scholar
  187. 187.
    Fonager K, Larsen H, Pedersen L, et al. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand 2000; 101(5): 289–94PubMedCrossRefGoogle Scholar
  188. 188.
    Hill BC, Verniaud WM, Rettig GM, et al. Relation between antiepileptic drug exposure of the infant and developmental potential. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 409–17Google Scholar
  189. 189.
    Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29(4): 459–67PubMedCrossRefGoogle Scholar
  190. 190.
    Nakane Y. The teratological problem of antiepileptic drugs. Folia Psychiatr Neurol Jpn 1980; 34(3): 277–87PubMedGoogle Scholar
  191. 191.
    van der Pol MC, Hadders-Algra M, Huisjes HJ, et al. Antiepileptic medication in pregnancy: late effects on the children’s central nervous system development. Am J Obstet Gynecol 1991; 164 (1 Pt 1): 121–8PubMedGoogle Scholar
  192. 192.
    Tomson T, Battino D, Bonizzoni E, et al. EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia 2004 Nov; 45(11): 1463–4PubMedCrossRefGoogle Scholar
  193. 193.
    Tomson T, Battino D, French J, et al. Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries. ETDP Workgroup on Teratogenicity-Anatomical. Epilepsy Behav 2007; 11(3): 277–82CrossRefGoogle Scholar
  194. 194.
    Nakane Y. Factors influencing the risk of malformations among infants born to epileptic mothers. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York Raven Press, 1982: 259–66Google Scholar
  195. 195.
    Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996 Dec; 75(6): 517–20PubMedCrossRefGoogle Scholar
  196. 196.
    Annegers JF, Elveback LR, Hauser WA, et al. Do anticonvulsants have a teratogenic effect? Arch Neurol 1974; 31(6): 364–73PubMedCrossRefGoogle Scholar
  197. 197.
    Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21(6): 663–80PubMedCrossRefGoogle Scholar
  198. 198.
    Dansky L. Outcome of pregnancy in epileptic women [PhD thesis]. Montreal, QC: McGill University, 1989Google Scholar
  199. 199.
    Meadow SR. Congenital abnormalities and anticonvulsant drugs. Proc R Soc Med 1970; 63(1): 48–9PubMedGoogle Scholar
  200. 200.
    Van Dyke DC, Hodge SE, Heide F, et al. Family studies in fetal phenytoin exposure. J Pediatr 1988 Aug; 113(2): 301–6PubMedCrossRefGoogle Scholar
  201. 201.
    Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001; 42(6): 750–3PubMedCrossRefGoogle Scholar
  202. 202.
    Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992; 42 (4 Suppl. 5): 111–8PubMedGoogle Scholar
  203. 203.
    Waziri M, Ionasescu V, Zellweger H. Teratogenic effect of anticonvulsant drugs. Am J Dis Child 1976; 130(9): 1022–3PubMedGoogle Scholar
  204. 204.
    Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001; 98(2): 168–75PubMedCrossRefGoogle Scholar
  205. 205.
    Ozkinay F, Yenigun A, Kantar M, et al. Two siblings with fetal hydantoin syndrome. Turk J Pediatr 1998; 40(2): 273–8PubMedGoogle Scholar
  206. 206.
    Karpathios T, Zervoudakis A, Venieris F, et al. Genetics and fetal hydantoin syndrome. Acta Paediatr Scand 1989; 78(1): 125–6PubMedCrossRefGoogle Scholar
  207. 207.
    Gardner RJ, Savarirayan R, Dunne KB, et al. Microlissencephaly with cardiac, spinal and urogenital defects. Clin Dysmorphol 2001; 10(3): 203–8PubMedCrossRefGoogle Scholar
  208. 208.
    Erickson JD. Facial and oral form in sibs of children with cleft lip with or without cleft palate. Ann Hum Genet 1974; 38(1): 77–88PubMedCrossRefGoogle Scholar
  209. 209.
    Malm H, Kajantie E, Kivirikko S, et al. Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology 2002 Aug 27; 59(4): 630–3PubMedCrossRefGoogle Scholar
  210. 210.
    Pashayan H, Pruzansky D, Qruzansky S. Are anticonvulsants teratogenic? Lancet 1971; II(7726): 702–3CrossRefGoogle Scholar
  211. 211.
    Dronamraju KR. Epilepsy and cleft lip and palate. Lancet 1970 Oct 24; II(7678): 876–7CrossRefGoogle Scholar
  212. 212.
    Abrishamchian AR, Khoury MJ, Calle EE. The contribution of maternal epilepsy and its treatment to the etiology of oral clefts: a population based case-control study. Genet Epidemiol 1994; 11(4): 343–51PubMedCrossRefGoogle Scholar
  213. 213.
    Kelly TE, Rein M, Edwards P. Teratogenicity of anticonvulsant drugs: IV, the association of clefting and epilepsy. Am J Med Genet 1984; 19(3): 451–8PubMedCrossRefGoogle Scholar
  214. 214.
    Friis ML. Epilepsy among parents of children with facial clefts. Epilepsia 1979; 20(1): 69–76PubMedCrossRefGoogle Scholar
  215. 215.
    Erickson JD, Oakley GP. Seizure disorder in mothers of children with orofacial clefts: a case-control study. J Pediatr 1974; 84(2): 244–6PubMedCrossRefGoogle Scholar
  216. 216.
    Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; II(8304): 937CrossRefGoogle Scholar
  217. 217.
    Lindhout D, Meinardi H. Spina bifida and in-utero exposure to valproate. Lancet 1984; II(8399): 396CrossRefGoogle Scholar
  218. 218.
    Greenberg G, Inman WH, Weatherall JA, et al. Maternal drug histories and congenital abnormalities. BMJ 1977 Oct 1; 2(6091): 853–6PubMedCrossRefGoogle Scholar
  219. 219.
    Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108(6): 997–1004PubMedCrossRefGoogle Scholar
  220. 220.
    Vajda FJ, O’Brien TJ, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003 Sep; 10(5): 543–9PubMedCrossRefGoogle Scholar
  221. 221.
    Bertollini R, Mastroiacovo P, Segni G. Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC). Eur J Epidemiol 1985; 1(1): 67–72PubMedCrossRefGoogle Scholar
  222. 222.
    Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000; 41(11): 1436–43PubMedCrossRefGoogle Scholar
  223. 223.
    Hernandez-Diaz S, Werler MM, Walker AM, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153(10): 961–8PubMedCrossRefGoogle Scholar
  224. 224.
    Kallen B, Robert E, Mastroiacovo P, et al. Anticonvulsant drugs and malformations: is there a drug specificity? Eur J Epidemiol 1989; 5(1): 31–6PubMedCrossRefGoogle Scholar
  225. 225.
    Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42 (4 Suppl. 5): 119–25PubMedGoogle Scholar
  226. 226.
    Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986; I(8494): 1392–3CrossRefGoogle Scholar
  227. 227.
    Annegers JF, Hauser WA, Elveback LR, et al. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978; 7(3): 241–7PubMedCrossRefGoogle Scholar
  228. 228.
    Rodriguez-Pinilla E, Arroyo I, Fondevilla J, et al. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000; 90(5): 376–81PubMedCrossRefGoogle Scholar
  229. 229.
    Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005 May; 21(5): 693–701PubMedCrossRefGoogle Scholar
  230. 230.
    Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006 Nov 28; 67(10): 1876–9PubMedCrossRefGoogle Scholar
  231. 231.
    Wide K, Winbladh B, Tomson T, et al. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev Med Child Neurol 2000 Feb; 42(2): 87–92PubMedCrossRefGoogle Scholar
  232. 232.
    Steinhausen HC, Losche G, Koch S, et al. The psychological development of children of epileptic parents: I. Study design and comparative findings. Acta Paediatr 1994; 83(9): 955–60Google Scholar
  233. 233.
    Gaily E, Kantola-Sorsa E, Granström ML. Intelligence of children of epileptic mothers. J Pediatr 1988; 113(4): 677–84PubMedCrossRefGoogle Scholar
  234. 234.
    Losche G, Steinhausen HC, Koch S, et al. The psychological development of children of epileptic parents: II, the differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994; 83(9): 961–6PubMedCrossRefGoogle Scholar
  235. 235.
    Fujioka K, Kaneko S, Hirano T, et al. A study of the psychomotor development of the offspring of epileptic mothers. In: Sato T, Shinagawa S, editors. Antiepileptic drugs and pregnancy. Amsterdam-Princeton-Geneva-Tokyo: Excerpta Medica, 1984Google Scholar
  236. 236.
    Jager-Roman E, Fating D, Koch S. Somatic parameters, diseases and psychomotor development in the offspring of epileptic parents. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: 1Raven Press, 1982: 425–32Google Scholar
  237. 237.
    Koch S, Gopfert-Geyer I, Jager-Roman E, et al. Anti-epileptic agents during pregnancy: a prospective study on the course of pregnancy, malformations and child development. Dtsch Med Wochenschr 1983; 108(7): 250–7PubMedCrossRefGoogle Scholar
  238. 238.
    Nomura Y, Takabe Y, Nomura Y. The physical and mental development of infants born to mothers treated with antiepileptic drugs. In: Sato T, Shinagawa S, editors. Antiepileptic drugs and pregnancy. Amsterdam: Excerpta Medica, 1984: 187–95Google Scholar
  239. 239.
    Beck-Mannagetta G, Janz D. Data on psychomotor and mental development in children of epileptic mothers: a retrospective study. In: Janz D, Dam M, Bossi L, et al., editors. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982: 443–5Google Scholar
  240. 240.
    Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89(4): 662–8PubMedCrossRefGoogle Scholar
  241. 241.
    Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994 Mar 9; 271(10): 767–70PubMedCrossRefGoogle Scholar
  242. 242.
    Hattig H, Helge H, Steinhausen H. Infants of epileptic mothers: development scores at 18 months. In: Wolf P, Dam M, Janz D, editors. Advances in epileptology. New York: Raven Press, 1987: 403–8Google Scholar
  243. 243.
    Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004 Nov; 75(11): 1575–83PubMedCrossRefGoogle Scholar
  244. 244.
    Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology 1982; 32(11): 1247–54PubMedCrossRefGoogle Scholar
  245. 245.
    Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70(1): 15–21PubMedCrossRefGoogle Scholar
  246. 246.
    Leavitt AM, Yerby MS, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992; 42 (4 Suppl. 5): 141–3PubMedGoogle Scholar
  247. 247.
    Wide K, Henning E, Tomson T, et al. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002; 91(4): 409–14PubMedCrossRefGoogle Scholar
  248. 248.
    Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32(5): 403–14PubMedCrossRefGoogle Scholar
  249. 249.
    Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62(1): 28–32PubMedCrossRefGoogle Scholar
  250. 250.
    Rovet J, Cole S, Nulman I, et al. Effects of maternal epilepsy on children’s neurodevelopment. Child Neuropsychol 1995; 1(2): 150–7CrossRefGoogle Scholar
  251. 251.
    Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005 Mar 22; 64(6): 949–54PubMedCrossRefGoogle Scholar
  252. 252.
    Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40(9): 1237–43PubMedCrossRefGoogle Scholar
  253. 253.
    Vanoverloop D, Schnell RR, Harvey EA, et al. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992; 14(5): 329–35PubMedCrossRefGoogle Scholar
  254. 254.
    Dessens AB, Boer K, Koppe JG, et al. Studies on long-lasting consequences of prenatal exposure to anticonvulsant drugs. Acta Paediatr Suppl. 1994; 404: 54–64PubMedCrossRefGoogle Scholar
  255. 255.
    Ohtsuka Y, Silver K, Lopes-Cendes I, et al. Effect of antiepileptic drugs on psychomotor development of offspring of epileptic mothers [abstract]. Epilepsia 1999; 40 Suppl. 2: 296Google Scholar
  256. 256.
    Eriksson K, Viinikainen K, Monkkonen A, et al. Children exposed to valproate in utero: population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005 Jul 16; 65(3): 189–200PubMedCrossRefGoogle Scholar
  257. 257.
    Viinikainen K, Eriksson K, Monkkonen A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav 2006 Dec; 9(4): 636–40PubMedCrossRefGoogle Scholar
  258. 258.
    Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. Implications for prevention. JAMA 1995 Dec 6; 274(21): 1698–702Google Scholar
  259. 259.
    Kirke PN, Molloy AM, Daly LE, et al. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993 Nov; 86(11): 703–8PubMedGoogle Scholar
  260. 260.
    Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995 Jan 21; 345(8943): 149–51PubMedCrossRefGoogle Scholar
  261. 261.
    Yates JR, Ferguson-Smith MA, Shenkin A, et al. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet 1987 May; 31(5): 279–87PubMedCrossRefGoogle Scholar
  262. 262.
    Botto LD, Moore CA, Khoury MJ, et al. Neural-tube defects. N Engl J Med 1999 Nov 11; 341(20): 1509–19PubMedCrossRefGoogle Scholar
  263. 263.
    Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol 1992; 8(1): 122–7PubMedGoogle Scholar
  264. 264.
    Hernandez-Diaz S, Werler MM, Walker AM, et al. Folie acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343(22): 1608–14PubMedCrossRefGoogle Scholar
  265. 265.
    Hiilesmaa VK, Teramo K, Granstrom ML, et al. Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome. BMJ (Clin Res Ed) 1983; 287(6392): 577–9CrossRefGoogle Scholar
  266. 266.
    Dansky LV, Andermann E, Rosenblatt D, et al. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987; 21(2): 176–82PubMedCrossRefGoogle Scholar
  267. 267.
    Dansky L, Wolfson C, Anderman E, et al. A multivariate analysis of risk factors for major congenital malformations in offspring of epileptic women [abstract]. Epilepsia 1989; 30: 678Google Scholar
  268. 268.
    Moore JL. The significance of folic acid for epilepsy patients. Epilepsy Behav 2005 Sep; 7(2): 172–81PubMedCrossRefGoogle Scholar
  269. 269.
    Stokes T, Juarez-Garcia A, Camosso-Stefinovic J, et al. Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners, 2004Google Scholar
  270. 270.
    Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005; 46 Suppl. 9: 117–24CrossRefGoogle Scholar
  271. 271.
    von Unruh GE, Froescher W, Hoffmann F, et al. Valproic acid in breast milk: how much is really there? Ther Drug Monit 1984; 6(3): 272–6CrossRefGoogle Scholar
  272. 272.
    Froescher W, Eichelbaum M, Niesen M, et al. Carbamazepine levels in breast milk. Ther Drug Monit 1984; 6(3): 266–71PubMedCrossRefGoogle Scholar
  273. 273.
    Kuhnz W, Koch S, Helge H, et al. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 1988; 11(3): 147–54PubMedGoogle Scholar
  274. 274.
    Johannessen SI, Helde G, Brodtkorb E. Levetiracetam concentrations in serum and in breast milk at birth and during lactation. Epilepsia 2005 May; 46(5): 775–7PubMedCrossRefGoogle Scholar
  275. 275.
    Shimoyama R, Ohkubo T, Sugawara K. Monitoring of zonisamide in human breast milk and maternal plasma by solid-phase extraction HPLC method. Biomed Chromatogr 1999; 13(5): 370–2PubMedCrossRefGoogle Scholar
  276. 276.
    Tomson T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther Drug Monit 2005 Dec; 27(6): 718–21PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Fondazione I.R.C.C.S. Istituto Neurologico ‘Carlo Besta’MilanItaly
  2. 2.Department of Clinical NeuroscienceKarolinska InstituteStockholmSweden

Personalised recommendations